Endologix Reports First Quarter 2017 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017.
“We are pleased with our progress during the quarter and our solid start to the year. Our top-line performance was driven by continued adoption of Ovation®. We’ve also made excellent progress in lowering our operating expenses by driving synergies from the merger with TriVascular last year. Additionally, shortly after the end of the quarter, we secured a new credit facility, which we anticipate will provide the resources we need to execute our strategic initiatives,” commented John McDermott, Endologix’s Chief Executive Officer. “Looking forward, we remain focused on providing value through our comprehensive portfolio of innovative aortic technologies.”
“We are pleased with our progress during the quarter and our solid start to the year. Our top-line performance was driven by continued adoption of Ovation®. We’ve also made excellent progress in lowering our operating expenses by driving synergies from the merger with TriVascular last year. Additionally, shortly after the end of the quarter, we secured a new credit facility, which we anticipate will provide the resources we need to execute our strategic initiatives,” commented John McDermott, Endologix’s Chief Executive Officer. “Looking forward, we remain focused on providing value through our comprehensive portfolio of innovative aortic technologies.”